Mazdutide and tirzepatide are both once-a-week injections studied for weight loss. They work on the same main hormone, GLP-1. Where they differ is the second hormone they work on. Tirzepatide adds GIP. Mazdutide adds glucagon.
That one difference is why people keep comparing them. In this article, we put the two side by side using only published trial results, and we link every number to its source. As with everything on our site, this is for research education only, not medical advice.
Key Takeaways
- Both drugs act on GLP-1. Tirzepatide also acts on GIP. Mazdutide also acts on glucagon.
- In its main trial, tirzepatide led to about 21% average weight loss at the highest dose after 72 weeks (Eli Lilly, 2022).
- Mazdutide led to about 11% to 18% average weight loss in its trials, depending on the dose and how long the trial ran (Innovent, 2025; BariatricPal, 2026).
- We could not find any published trial that tested the two against each other, so these numbers are not a fair head-to-head.
Mazdutide vs Tirzepatide at a Glance
Here is the short version before we go into detail.
| Tirzepatide | Mazdutide | |
|---|---|---|
| Made by | Eli Lilly | Innovent Biologics in China, under license from Eli Lilly. Eli Lilly is testing it in the US. |
| Works on | GLP-1 + GIP | GLP-1 + glucagon |
| Brand names | Mounjaro, Zepbound | Not sold outside China |
| How often | Once a week, injection under the skin | Once a week, injection under the skin |
| Doses tested in main trials | 5, 10 and 15 mg | 4 and 6 mg (GLORY-1), 9 mg (GLORY-2), 3 to 16 mg (US phase 2) |
| Biggest average weight loss in a main trial | 20.9% at 72 weeks, 15 mg (Eli Lilly, 2022) | 18.1% at 32 weeks, 16 mg (BariatricPal, 2026) |
| Where approved | Prescription medicine | China only, since June 2025 (Innovent, 2025) |
| Most common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting |
The doses are the ones tested in trials. They are not recommendations.
How They Work: Glucagon vs GIP
Both drugs copy GLP-1, a hormone your gut releases after you eat. GLP-1 slows hunger and helps control blood sugar. The big difference is the second hormone each drug copies.
What is mazdutide?
Mazdutide is a once-weekly peptide that switches on two receptors: GLP-1 and glucagon. A drug that switches on two receptors at once is called a “dual agonist”. In research papers, you may see it called IBI362 or LY3305677 (CenterWatch).
Glucagon is a hormone that tells your liver to release stored energy. In drugs like mazdutide, researchers study it for two reasons: it may help the body use more energy, and it may lower fat stored in the liver.
What is tirzepatide?
Tirzepatide is also a once-weekly dual agonist, but its two receptors are GLP-1 and GIP. GIP is another gut hormone. Its main job is to help your body release insulin after a meal. Tirzepatide is sold as Mounjaro and Zepbound.
Why the second hormone matters
Here is a simple way to picture it. Both drugs press the same brake on hunger (GLP-1). Tirzepatide adds a helper for insulin (GIP). Mazdutide adds a signal that may push the body to burn more energy and clear fat from the liver (glucagon).
Retatrutide, a third drug still in trials, combines all three hormones. We compare it further down.
Weight Loss Results in Clinical Trials
In their own trials, both drugs led to much more weight loss than placebo. Placebo is a dummy injection with no drug in it, used so researchers can see what the drug itself does.
Tirzepatide: the SURMOUNT-1 trial
SURMOUNT-1 followed adults with obesity or overweight for 72 weeks.
| Dose | Average weight change after 72 weeks |
|---|---|
| 5 mg | -15.0% |
| 10 mg | -19.5% |
| 15 mg | -20.9% |
| Placebo | -3.1% |
Sources: Eli Lilly, 2022; Bariatric News
Mazdutide: three trials so far
Mazdutide has been tested in two large trials in China and one trial in the US.
| Trial | Who took part | Length | Dose | Average weight change |
|---|---|---|---|---|
| GLORY-1 (phase 3) | 610 Chinese adults with obesity or overweight | 48 weeks | 4 mg / 6 mg | -11.0% / -14.0% (placebo +0.3%) |
| GLORY-2 (phase 3) | Chinese adults with moderate to severe obesity | 60 weeks | 9 mg | -16.65% (placebo -1.50%) |
| US phase 2 (Eli Lilly) | 179 US adults with obesity or overweight | 32 weeks | 3 to 6 mg / 10 mg / 16 mg | -7.3% / -15.6% / -18.1% (placebo -0.9%) |
Sources: GLORY-1 (Innovent, 2025; 2 Minute Medicine), GLORY-2 (Drug Topics, 2026), US phase 2 (BariatricPal, 2026; The Lancet Diabetes & Endocrinology)
A few things stand out:
- In GLORY-1, about half of the people on 6 mg (49.5%) lost 15% or more of their body weight (Innovent, 2025; 2 Minute Medicine).
- In the US trial, higher doses led to more weight loss. The 16 mg dose reached 18.1% by week 32.
- In the US trial, weight kept going down after week 32, all the way to the end of the trial at week 48 (BariatricPal, 2026; Pharmacally, 2026).
Why Different Websites Show Different Numbers
If you read about these drugs on a few websites, you may see different numbers for the same trial. That is usually not a mistake. Trials report two kinds of averages:
- Everyone who started: this counts every person who began the trial, including people who stopped taking the drug. This number is usually lower.
- People who stayed on the drug: this counts only the people who kept taking it. This number is usually higher.
Here is a real example. In SURMOUNT-1, the 15 mg dose of tirzepatide shows 20.9% weight loss when you count everyone who started, and 22.5% when you count only people who stayed on it (Eli Lilly, 2022; Bariatric News). In GLORY-1, the 6 mg dose of mazdutide shows 14.0% and 14.8% in the same way (Innovent, 2025).
In this article, we use the “everyone who started” number unless we say otherwise. It is the more careful choice, because it reflects what happens in real life when some people stop.
Can You Compare Mazdutide and Tirzepatide Directly?
Not fairly, at least not yet. We could not find any published trial that gave one group mazdutide and another group tirzepatide.
Comparing their separate trials is a bit like comparing two runners who ran on different tracks on different days. A few reasons the numbers do not line up:
- Different people. Two of the three mazdutide trials were run in Chinese adults. SURMOUNT-1 was a separate trial with its own group of people.
- Different lengths. The trials ran anywhere from 32 to 72 weeks, and weight loss often keeps going over time.
- Different doses. Each drug was tested at its own set of doses.
The only way to settle which one leads to more weight loss is a trial that tests them side by side.
Mazdutide vs Semaglutide: The DREAMS-3 Trial
While there is no mazdutide vs tirzepatide trial, there is one that put mazdutide against semaglutide. It is called DREAMS-3. It compared mazdutide 6 mg with semaglutide 1 mg for 32 weeks in adults with type 2 diabetes and extra weight.
| Result after 32 weeks | Mazdutide 6 mg | Semaglutide 1 mg |
|---|---|---|
| Average weight loss | 10.29% | 6% |
| Drop in HbA1c | 2.03% | 1.84% |
HbA1c is a blood test that shows your average blood sugar over about 3 months.
Sources: HCPLive, 2025; TechTarget, 2025
Semaglutide is also the drug tirzepatide is most often measured against, which we look at closely in our comparison of tirzepatide vs semaglutide.
Side Effects Compared
For both drugs, the most common side effects affect the stomach and gut (HCPLive, SURMOUNT-1; HCPLive, DREAMS-3).
Tirzepatide side effects in SURMOUNT-1
| Side effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 24.6% | 33.3% | 31.0% | 9.5% |
| Diarrhea | 18.7% | 21.2% | 23.0% | 7.3% |
| Vomiting | 8.3% | 10.7% | 12.2% | 1.7% |
| Constipation | 16.8% | 17.1% | 11.7% | 5.8% |
| Stopped because of side effects | 4.3% | 7.1% | 6.2% | 2.6% |
Sources: Eli Lilly, 2022; Bariatric News
Mazdutide side effects
Nausea, diarrhea and vomiting were the most common side effects in the mazdutide trials, and most were mild to moderate (Innovent, 2025; HCPLive, 2025). We have not listed exact percentages here, because the sources we checked report them differently.
One number is clear. In the US trial, 20% of people on the highest dose (16 mg) stopped taking it because of side effects, mostly stomach problems (BariatricPal, 2026; Pharmacally, 2026).
So the pattern is simple: higher doses brought more weight loss, but also more people who could not stay on the drug. For a wider look at the research on how safe weight loss peptides are, we cover that question on its own.
What Glucagon May Add: Less Liver Fat
This is where mazdutide’s glucagon side may matter most. In GLORY-1, some of the people in the trial had MRI scans of their liver. Among those who started with 5% or more fat in the liver, liver fat dropped after 48 weeks, while it went up in the placebo group (Innovent, 2025; Patsnap Synapse).
| Group | Change in liver fat after 48 weeks |
|---|---|
| Mazdutide 4 mg | -63.3% |
| Mazdutide 6 mg | -73.2% |
| Placebo | +8.2% |
One honest note: this was a small, extra analysis done in only part of the trial, not one of the trial’s main goals. It is promising, but it needs bigger studies before anyone can say for sure.
Where Each One Is Approved
- Tirzepatide is a prescription medicine, sold as Mounjaro and Zepbound.
- Mazdutide was approved in China in June 2025 for long-term weight management in adults (Innovent, 2025; Shanghai Government, 2025). It is not available as a medicine in the US. Eli Lilly has tested it in US trials (CenterWatch)
Mazdutide vs Retatrutide vs Tirzepatide
Many people who look up these two drugs also ask about retatrutide. Retatrutide is an Eli Lilly drug that works on all three hormones: GLP-1, GIP and glucagon. It is still being tested in trials.
| Tirzepatide | Mazdutide | Retatrutide | |
|---|---|---|---|
| Works on | GLP-1 + GIP | GLP-1 + glucagon | GLP-1 + GIP + glucagon |
| Biggest average weight loss reported | 20.9% at 72 weeks | 18.1% at 32 weeks | 24.2% at 48 weeks (phase 2, highest dose) |
| Status | Prescription medicine | Approved in China only | Still in trials |
Sources: tirzepatide (Eli Lilly, 2022), mazdutide (BariatricPal, 2026), retatrutide (MDedge, 2023)
The same warning applies here. These are separate trials with different people and lengths, so the table shows what each drug did in its own study, not which one is best. In the retatrutide trials, the dose was raised step by step over several weeks, which is worth knowing when you read its results.
“Mazdutide Peptide” Sold Online: Is It the Same Thing?
No. Products sold online as “mazdutide peptide” or “research mazdutide” are not the approved medicine. Nobody checks their purity, strength, or safety the way a medicine is checked, so you cannot be sure what is actually in the vial. The trial results in this article apply only to the drug used in those trials.
Frequently Asked Questions
Is mazdutide stronger than tirzepatide?
We do not know yet. No published trial has compared them directly, and their separate trials used different people, doses and lengths.
Can you get mazdutide in the US?
Not as a medicine. In the US, it has only been given to people taking part in clinical trials (CenterWatch).
Is there something stronger than tirzepatide?
Retatrutide showed larger weight loss in its own phase 2 trial, with 24.2% at 48 weeks on the highest dose (MDedge, 2023). But it is still being tested, and it has not been compared with tirzepatide in the same trial.
What is the difference between GIP and glucagon?
GIP helps your body release insulin after a meal. Glucagon tells your liver to release stored energy. Tirzepatide uses GIP, and mazdutide uses glucagon.
Is mazdutide the same as survodutide?
No. Both work on GLP-1 and glucagon, but survodutide is a different drug made by Boehringer Ingelheim (Zealand Pharma; Fierce Biotech).
Disclaimer
This article is for research education only. It is not medical advice, and it does not recommend any drug, dose or product. The numbers here come from published clinical trials and company reports, and they may change as new results come out.
Products sold online as research peptides are not approved medicines and are not intended for human or veterinary use. Please talk to a qualified healthcare professional before making any decision about your health or weight.
Sources
- Eli Lilly. Tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1. April 28, 2022.
- HCPLive. SURMOUNT-1: Tirzepatide provides significant, sustained weight loss in obesity.
- Bariatric News. SURMOUNT-1: tirzepatide results in 22.5% weight loss in adults with obesity or overweight.
- Innovent Biologics. GLORY-1 published in the New England Journal of Medicine. May 2025.
- 2 Minute Medicine. Mazdutide significantly reduces weight in adults with overweight or obesity. July 2025.
- Drug Topics. Mazdutide shows weight reductions for patients with obesity (GLORY-2, JAMA). June 2026.
- BariatricPal. Phase 2 mazdutide trial reports greater weight loss at higher doses. August 2026.
- The Lancet Diabetes & Endocrinology. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based phase 2 trial. 2026.
- Pharmacally. Mazdutide produces up to 18.1% weight loss in US phase 2 obesity trial. 2026.
- HCPLive. Mazdutide demonstrates superiority to semaglutide in type 2 diabetes and obesity. October 2025.
- TechTarget. Innovent-Lilly’s mazdutide outdoes Novo’s semaglutide in phase 3 trial. 2025.
- Patsnap Synapse. Innovent reports 80.2% liver fat reduction in phase 3 GLORY-1 study.
- Innovent Biologics. Mazdutide receives approval in China for chronic weight management. June 27, 2025.
- Shanghai Municipal Government. Weight loss medicine mazdutide approved for commercialization in China. July 2, 2025.
- CenterWatch. A study of LY3305677 compared with placebo in adults with obesity or overweight (NCT06124807).
- MDedge. Triple G agonist hits new weight loss heights (retatrutide phase 2, NEJM 2023).
- Zealand Pharma. Survodutide (BI 456906) GLP-1/glucagon dual agonist.
- Fierce Biotech. Boehringer links dual agonist to 16.6% weight loss in phase 3.